Modality
ASO
MOA
Anti-Aβ
Target
ALK
Pathway
Sphingolipid
MigraineProstate Ca
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
~Jun 2019
→ ~Sep 2020
Phase 2
Dec 2020
→ Nov 2029
Phase 2Current
NCT07707836
1,709 pts·Migraine
2020-12→2029-11·Completed
1,709 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-11-113.6y awayPh2 Data· Migraine
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2029-11-11 · 3.6y away
Migraine
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07707836 | Phase 2 | Migraine | Completed | 1709 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Niralucimab | Ionis | Phase 1 | ALK |